Evidence map›Paper›PMID 32005233›Full record

ArticleMalaria journal2020

The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput.

Sage Z Davis, Puspendra P Singh, Katelyn M Vendrely, Douglas A Shoue, Lisa A Checkley, Marina McDew-White, Katrina A Button-Simons, Zione Cassady, Mackenzie A C Sievert, Gabriel J Foster and 3 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Selective targeting ofAntimicrobial agents and chemotherapy · 2026
    Article
  4. High throughput quantitative tracking ofbioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. AmBio · 2024
    Article
  10. Mutation in the 26S proteasome regulatory subunitFrontiers in cellular and infection microbiology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Frontiers in pharmacology · 2021
    Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Sage Z DavisEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Puspendra P SinghEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Katelyn M VendrelyEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Douglas A ShoueEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Lisa A CheckleyEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Marina McDew-WhiteTexas Biomedical Research Institute, San Antonio, TX, USA.
Katrina A Button-SimonsEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Zione CassadyEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Mackenzie A C SievertEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Gabriel J FosterEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
François H NostenShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Mae Sot, Thailand.
Timothy J C AndersonTexas Biomedical Research Institute, San Antonio, TX, USA.
Michael T FerdigEck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA. ferdig.1@nd.edu.
University of Notre Dame · USTexas Biomedical Research Institute · USMahidol Oxford Tropical Medicine Research Unit · TH

Funding

Systems genetics of artemisinin resistanceP01AI127338 · NIAID · UNIVERSITY OF NOTRE DAME · PI Michael T Ferdig, Ashley M Vaughan · 2017 to 2026
$21.3M
Mapping Drug Resistance Genes in Plasmodium falciparumR37AI048071 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J · 2012 to 2021
$7.9M
National Institute of Allergy and Infectious Diseases AI127338NIAID NIH HHS P01 AI127338NIAID NIH HHS R37 AI048071
6 · The paper itself

Abstract

backgroundTracking and understanding artemisinin resistance is key for preventing global setbacks in malaria eradication efforts. The ring-stage survival assay (RSA) is the current gold standard for in vitro artemisinin resistance phenotyping. However, the RSA has several drawbacks: it is relatively low throughput, has high variance due to microscopy readout, and correlates poorly with the current benchmark for in vivo resistance, patient clearance half-life post-artemisinin treatment. Here a modified RSA is presented, the extended Recovery Ring-stage Survival Assay (eRRSA), using 15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives, including parasite isolates with and without kelch13 mutations.

methodsPlasmodium falciparum cultures were synchronized with single layer Percoll during the schizont stage of the intraerythrocytic development cycle. Cultures were left to reinvade to early ring-stage and parasitaemia was quantified using flow cytometry. Cultures were diluted to 2% haematocrit and 0.5% parasitaemia in a 96-well plate to start the assay, allowing for increased throughput and decreased variability between biological replicates. Parasites were treated with 700 nM of dihydroartemisinin or 0.02% dimethyl sulfoxide (DMSO) for 6 h, washed three times in drug-free media, and incubated for 66 or 114 h, when samples were collected and frozen for PCR amplification. A SYBR Green-based quantitative PCR method was used to quantify the fold-change between treated and untreated samples.

results15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives were assayed using the eRRSA. Due to the large number of pyknotic and dying parasites at 66 h post-exposure (72 h sample), parasites were grown for an additional cell cycle (114 h post-exposure, 120 h sample), which drastically improved correlation with patient clearance half-life compared to the 66 h post-exposure sample. A Spearman correlation of - 0.8393 between fold change and patient clearance half-life was identified in these 15 isolates from Southeast Asia, which is the strongest correlation reported to date.

conclusionseRRSA drastically increases the efficiency and accuracy of in vitro artemisinin resistance phenotyping compared to the traditional RSA, which paves the way for extensive in vitro phenotyping of hundreds of artemisinin resistant parasites.

Indexed as

AntimalarialsArtemisininsBenzothiazolesDiaminesDrug ResistanceErythrocytesFlow CytometryFluorescent DyesHalf-LifeHumansMalaria, FalciparumOrganic ChemicalsParasitemiaPlasmodium falciparumPovidoneQuinolinesAntimalarialsartemisininArtemisininsartenimolBenzothiazolesDiaminesFluorescent DyesOrganic ChemicalsPercollPovidoneQuinolinesSilicon DioxideSYBR Green IArtemisinin resistancekelch13Ring-stage survival assay

Identifiers

PMID32005233
PMCPMC6995136
OpenAlexW3011679891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.